No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology firm committed to advancing and bringing to market innovative cancer immunotherapies. Its fundamental objective is to leverage and direct a patient's own immune system to identify and eradicate cancerous cells. The company currently oversees six ongoing Phase 2 clinical trials. Notably, its primary therapeutic candidate, lifileucel, is under investigation in two of these studies: C-144-01 for advanced melanoma and C-145-04 for cervical cancer that is recurrent, metastatic, or persistent. Furthermore, another candidate, LN-145, is being assessed in study C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics maintains strategic alliances and licensing arrangements with esteemed institutions including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Incorporated in 2007 and situated in San Carlos, California, the organization was formerly known as Lion Biotechnologies, Inc. until its rebranding in June 2017.
www.iovance.comNo one on the platform currently holds 0JDK.L.
No tracked institution reports a position in 0JDK.L as of their last filing.
No one on the platform has traded 0JDK.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 60.6% | |||||
| Profit Margin % | -148.4% | |||||
| Free Cash Flow Margin % | -127.6% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $402M | +55.8% | $-0.48 | $-0.53–$-0.43 | — | 1 |
| 2027 | $557M | +38.8% | $-0.25 | $-0.27–$-0.22 | — | 1 |
| 2028 | $837M | +50.2% | $0.10 | $0.09–$0.11 | — | 1 |
| 2029 | $1.1B | +27.4% | $0.20 | $0.18–$0.22 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.13 | $-0.11 | +17.6% |
| 2026-05-07 | $-0.15 | $-0.19 | -23.7% |
| 2026-02-24 | $-0.17 | $-0.18 | -2.9% |
| 2025-11-06 | $-0.26 | $-0.25 | +2.7% |
| 2025-08-07 | $-0.28 | $-0.33 | -18.0% |
| 2025-05-08 | $-0.24 | $-0.36 | -48.8% |
| 2025-02-27 | $-0.27 | $-0.26 | +3.8% |
| 2024-11-08 | $-0.30 |
| $-0.28 |
| +6.3% |
| +3.69% |
| $371M |
| — |
| 0IIM.LEsperion Therapeutics, Inc. | $3.19 | +0.14% | $707M | — |
| 0IV3.LGeron Corporation | $1.31 | +0.15% | $876M | — |
Source: Financial Modeling Prep · peers by sector/industry